Sagent recalls more of its antibiotics manufactured in India

India flag

Sagent Pharmaceuticals ($SGNT) is widening its recall of antibiotics manufactured by one of its India-based contractors after a customer complained that small, dark particulate matter were found in the solution after it was reconstituted.

The latest action falls on the heels of a recall that came earlier this summer of 3,990 vials of oxacillin for injection. The Schaumburg, IL-based drug company, which specializes in sterile injectables, had another antibiotic-related recall earlier this year that involved a lot of an antifungus treatment that it said might be contaminated with an antibiotic. 

According to the most recent FDA Enforcement Report, Sagent announced a nationwide recall of one lot of oxacillin for injection manufactured by India-based Astral SteriTech. The foreign matter found in the vials was identified as iron oxide.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The company said in a release that it was unaware of any problems that might have resulted from patients using oxacillin from the recalled lot.

Although Sagent is on the cusp of becoming part of a Japanese company, for the time being it remains responsible for any recalls. Last month, Nichi-Iko said it would spend $736 million to buy Sagent in a deal it expects to close by the end of September.

- here’s the FDA notification

Read more:
Sagent recalls antibiotic after customers complain of particulates 
Japanese drugmaker buying Sagent to get U.S. beachhead
Sagent recalls fluconazole contaminated with antibiotic

Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.